FAM-TRASTUZUMAB DERUXTECAN-NXKI
Manufacturer: Daiichi Sankyo Inc.
Score: 141.0
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low breast cancer, HER2-mutant non-small cell lung cancer, HER2-positive gastric cancer, and other HER2-positive solid tumors. The drug has shown efficacy in clinical trials, but it also carries important safety risks, including interstitial lung disease and embryo-fetal toxicity. Dosing recommendations vary by condition, and special population considerations include use during pregnancy, nursing, pediatric use, and geriatric use.
Interstitial lung disease and embryo-fetal toxicity
Dose adjustments may be necessary for adverse reactions, including interstitial lung disease, neutropenia, thrombocytopenia, and left ventricular dysfunction
5.4 mg/kg every 3 weeks
Not established
6.4 mg/kg every 3 weeks
Not established